4.6 Article

Peripheral magnetic theta burst stimulation to muscles can effectively reduce spasticity: a randomized controlled trial

Journal

Publisher

BMC
DOI: 10.1186/s12984-022-00985-w

Keywords

Spasticity; Theta Burst Stimulation; Peripheral Magnetic Stimulation; Botulinum Toxin Dose

Funding

  1. Science & Technology Development Fund (STDF) in Egypt [2893]

Ask authors/readers for more resources

The study demonstrated that peripheral intermittent theta burst stimulation (piTBS) can significantly reduce spasticity, especially when applied directly on spastic muscles. It has shown promising results in reducing spasticity and Botulinum toxin dose without compromising treatment efficacy, thus providing a potential alternative to current therapeutic options.
Background Spasticity is a common complication of many neurological diseases and despite contributing much disability; the available therapeutic options are limited. Peripheral magnetic stimulation is one promising option. In this study, we investigated whether peripheral intermittent theta burst stimulation (piTBS) will reduce spasticity when applied directly on spastic muscles. Methods In this sham-controlled study, eight successive sessions of piTBS were applied directly to spastic muscles with supra threshold intensity. Assessment was done by modified Ashworth scale (mAS) and estimated Botulinum toxin dose (eBTD) at baseline and after the 8th session in both active and sham groups. Results A total of 120 spastic muscles of 36 patients were included in the analysis. Significant reduction of mAS and eBTD was found in the active compared to sham group (p < 0.001). The difference in mAS was also significant when tested in upper limb and lower limb subgroups. The degree of reduction in mAS was positively correlated with the baseline scores in the active group. Conclusion piTBS could be a promising method to reduce spasticity and eBTD. It consumes less time than standard high frequency protocols without compromising treatment efficacy. Trial registration: Clinical trial registry number: PACTR202009622405087. Retrospectively Registered 14th September, 2020.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available